Antiinfective & coagulation
Antimicrobial peptides, anticoagulants, hemostatic agents, and host-defense candidates.
Questions
What does the Antiinfective and coagulation category cover?
The sampled monographs span Gram-positive antibiotics such as daptomycin and vancomycin, the Gram-negative antibiotic colistin, and the antithrombotic medicines bivalirudin and eptifibatide. The category is an atlas navigation group, not a claim that these substances share a mechanism or clinical role.
Are all sampled Antiinfective and coagulation entries currently approved in every jurisdiction?
No. The sampled monographs document current US approvals, but jurisdictional status differs. Bivalirudin's EU authorization was withdrawn in 2018, and eptifibatide's EU central authorization was withdrawn in 2026. Each monograph's development table is the source for its jurisdiction-specific status.
What evidence distinctions appear among the sampled Antiinfective and coagulation entries?
Daptomycin and vancomycin have established roles against serious Gram-positive infections, while colistin's monograph describes older evidence, observational cohorts, and small trials. Bivalirudin's monograph reports similar ischemic outcomes with less major bleeding than its comparator in REPLACE-2. These conclusions are entity- and indication-specific.
How should approval be interpreted in this category?
Approval applies to a named product, indication, and jurisdiction, not to the category as a whole. The atlas methodology prioritizes current official product information and records time-sensitive statuses. A category placement does not transfer one medicine's evidence or authorization to another.
What is a key limitation when comparing colistin with newer category entries?
Colistin was not evaluated under modern approval standards, and its monograph relies on older literature, recent pharmacology work, observational cohorts, and small trials. That evidence base should not be treated as equivalent to the modern development records summarized for daptomycin, bivalirudin, or eptifibatide.
Join the atlas. Get the evidence updates.
Receive concise notes when peptide evidence, status, or source records change.